ISMP highlights potential safety issues with Multaq
This article was originally published in Scrip
Executive Summary
Evidence is accumulating that the potential risks of Sanofi-Aventis's new anti-arrhythmic drug Multaq (dronedarone) have been underestimated according to the US Institute for Safe Medication Practices (ISMP), an independent group that monitors FDA MedWatch reports.